This plenary will review the effect of CFTR dysfunction and CFTR restoration on both inflammation and mucociliary clearance in individuals with CF. Current and future therapeutic strategies to address inflammation and mucociliary clearance will be discussed, as well as how these strategies have potential to benefit both those patients using CFTR modulators and those not eligible for modulators.
Identify current strategies to develop new therapies that treat inflammation in cystic fibrosis.
Identify current strategies to develop new therapies that improve mucociliary clearance in cystic fibrosis.
Describe the impact of CFTR modulators on inflammation and mucociliary clearance and why continued development of therapies is needed.
Division Head of Respiratory Medicine
You must be logged in and own this session in order to